Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for Vanda Pharmaceuticals Inc
10.76
-0.28 (-2.54%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.62 - 11.15
52 week 8.34 - 19.25
Open 11.05
Vol / Avg. 506,966.00/755,156.00
Mkt cap 426.65M
P/E 35.24
Div/yield     -
EPS 0.31
Shares 33.90M
Beta 1.97
Inst. own 142%
May 6, 2015
Q1 2015 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 19, 2015
Q4 2014 Vanda Pharmaceuticals Inc Earnings Call - Webcast
Feb 19, 2015
Q4 2014 Vanda Pharmaceuticals Inc Earnings Release
Feb 3, 2015
Vanda Pharmaceuticals Inc at Canaccord Genuity Rare Disease, BioPharma One-on-One Day
Dec 23, 2014
Vanda Pharmaceuticals Inc. Commercialization plans for Fanapt Conference Call - Webcast
Dec 3, 2014
Vanda Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 453.60% 40.25%
Operating margin 453.44% 40.00%
EBITD margin - -110.25%
Return on average assets 222.93% 12.81%
Return on average equity 345.49% 19.70%
Employees 53 -
CDP Score - -

Address

Suite 300E, 2200 Pennsylvania Ave NW
WASHINGTON, DC 20037
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. The Company´┐Żs product portfolio includes: HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24); Fanapt (iloperidone), a product for the treatment of schizophrenia, the oral formulation; and VLY-686 (tradipitant), a small molecule neurokinin-1 receptor (NK-1R) antagonist. . Novartis has exclusive commercialization rights to all formulations of Fanapt in the United States and Canada. Novartis is responsible for the further clinical development activities in the United States and Canada.

Officers and directors

Howard H. Pien Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 72
Bio & Compensation  - Reuters
Steven K. Galson M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 51
Bio & Compensation  - Reuters
H. Thomas Watkins Independent Director
Age: 61
Bio & Compensation  - Reuters